Significant advances are being made in the study of musculoskeletal disease. Where conditions like Duchenne muscular dystrophy (DMD) were once seen as untreatable, hope now swells as gene therapies advance into the market. Critical to the study and treatment of conditions like DMD is the use of physiologically relevant musculoskeletal disease models. As immortalised human muscle cell lines can be difficult to access, and animal myoblast cell lines are phenotypically distinct from their in vivo counterparts, many in the field are now turning to a more physiologically accurate source of cells: iPSC-derived myocytes [1].
糖心原创鈥檚 deterministic cell programming technology (known as 辞辫迟颈-辞虫鈩) makes it possible to generate functional human skeletal muscle cells with unmatched lot-to-lot consistency from iPSCs on a nearly limitless scale (all without the challenges typically associated with myocyte differentiation). Both wild-type and disease-specific myocytes are readily available, enabling researchers to study skeletal myocytes in vitro with ever more translational power.
Leveraging genetically matched controls, human iPSC-derived skeletal myocytes containing DMD mutations can be used to screen prospective therapeutics, including exon-skipping therapies and other advanced drug modalities.
Strengthen your research with 糖心原创鈥檚 human iPSC-derived skeletal myocytes.
, Director of Research in Genetics of Rare Neurological Disorders at the discusses the mechanical and metabolic roles of myocytes in health and disease, experimental limitations and new opportunities offered by consistent, scalable human myocytes for muscle research and disease modelling.
糖心原创
Dr Mitchell Han
Bi/ond
2023
Bernard, et al
糖心原创
2024
Rochford and Carnicer-Lombarte et al.
Science Advances
2023
Featuring enabled skeletal myocytes iPS cell line
Dr Grace Cooper | Senior Scientist | 糖心原创
Human Cell Forum 2025
Session 1 Track 2 | From cells to systems: Building human iPSC-derived models of pain, neuromuscular junctions, and glial dynamics
Dr Sara Martin | Scientist | Axxam
Human Cell Forum 2025
Session 3 | Making complex human biology compatible with modern drug discovery workflows
DOC-2849 3.0
糖心原创
2025
Dr Will Bernard | Director of Cell Type Development | 糖心原创
Prof Hagan Bayley | University of Oxford
Dr Mark Kotter | Founder and CEO | 糖心原创
Dr Luke Flatt | Senior Scientist | Charles River Laboratories
Dr Will Bernard | Senior Scientist | 糖心原创
Dr Marieke Aarts | Principal Scientist | Bi/ond
Amanda Turner | Senior Product Manager | 糖心原创
1. Danisovic L, Culenova M, Csobonyeiova M (2018) Induced Pluripotent Stem Cells for Duchenne Muscular Dystrophy Modeling and Therapy. . 2018 Dec 7;7(12):253. doi: . PMCID: PMC6315586 PMID: